Novo Nordisk, the Danish pharmaceutical company, is planning to launch its popular obesity drug, Wegovy, in Germany this month. However, the high costs and limited supply could hinder its rollout and impact patient access. While more than half of Germany’s population is overweight, the country’s strict legislation means that weight loss medications are not covered …
A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen announced on Tuesday that it anticipates a reduction of about 1,000 jobs, representing approximately 11% of its workforce, in an effort to cut costs as the biotech company prepares for the launch of its newly approved Alzheimer’s drug, Leqembi. This comes after Biogen already …
Kenvue, the consumer health business spun out by Johnson & Johnson earlier this year, is set to see a reduction of at least 80% in Johnson & Johnson’s stake through a stock exchange offer. The company currently owns 89.6% of Kenvue’s common stock, which amounts to over 1.72 billion shares. The exchange offer, also known …
A doctor is administering a vaccine to a baby boy. Karl Tapales | Moment | Getty Images Sanofi anticipates the release of its infant RSV shot in the United States before the respiratory virus season this fall, according to a company spokesperson. The Food and Drug Administration granted approval on Monday for Beyfortus, a monoclonal …
In Rocky Mount, North Carolina, a tornado caused damage to a Pfizer pharmaceutical factory two days ago. Aerial images show the extent of the destruction. Despite this, Pfizer has reported that the drug manufacturing areas of the plant do not seem to have suffered major damage. Sean Rayford | Getty Images Pfizerr has announced that …
Thibaut Mongon, CEO of Kenvue Inc., Johnson & Johnson’s consumer-health business, spoke in a recent interview to mark the company’s IPO at the New York Stock Exchange (NYSE) on May 4, 2023. Brendan Mcdermid | Reuters Kenvue CEO Thibaut Mongon stated that while consumers have reduced spending due to inflation, they continue to invest in …
Thibaut Mongon, CEO, and Paul Ruh, CFO of Kenvue Inc., Johnson & Johnson’s consumer-health business, pose together during the company’s IPO at the New York Stock Exchange (NYSE) in New York City, U.S., on May 4, 2023. Brendan McDermid | Reuters Johnson & Johnson announced that its shareholders will soon have the opportunity to exchange …
Kenvue’s stock experienced a decline on Thursday, despite the fact that the consumer health company exceeded expectations for second-quarter revenue and earnings in its first quarterly report since becoming independent from Johnson & Johnson two months ago. In addition to this success, Kenvue CEO Thibaut Mongon expressed optimism for the company’s sales outlook in 2023, …
Johnson & Johnson, a leading healthcare company, reported second-quarter revenue and adjusted earnings that surpassed Wall Street’s expectations. This impressive performance was driven by strong sales from the company’s medtech business, which offers surgical, orthopedic, and vision devices. The increased demand for non-urgent surgeries among older adults, who postponed these procedures during the COVID-19 pandemic, …
Pfizer announced on Wednesday that its experimental vaccine targeting Group B Streptococcus (GBS) has shown promising results in mid-stage clinical trials. GBS is a potentially deadly bacterial disease responsible for vaginal and urinary tract infections, as well as newborn infections like meningitis and septicemia. This vaccine, if approved, could be the world’s first shot to …